IGC Pharma, Inc. (IGC) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Potomac, MD, United States. The current CEO is Ram Mukunda.
IGC has IPO date of 2006-05-24, 67 full-time employees, listed on the NYSE, a market capitalization of $30.64M.
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
